You are currently viewing Generative Artificial Intelligence (AI) In Pharmaceutical Market Overview: Size, Growth Drivers, Trends And Competitive Landscape
Generative Artificial Intelligence (AI) In Pharmaceutical Market Analysis

With a focus on actionable insights and strategic value, The Business Research Company’s 2026 market reports include market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights.

How Much Will The Generative Artificial Intelligence (AI) In Pharmaceutical Market Be Worth By 2030?

The generative artificial intelligence (AI) in pharmaceutical market size has experienced rapid growth in recent years. It is projected to increase from $2.43 billion in 2025 to $3.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 31.2%. This historical expansion is attributable to increasing r&d investments in pharmaceuticals, a rise in chronic diseases, the growing adoption of AI in early-stage drug discovery, the expansion of the biologics market, and the availability of large-scale molecular datasets.

The generative artificial intelligence (AI) in pharmaceutical market size is set to experience substantial expansion in the coming years. It is projected to reach $9.36 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 30.9%. This anticipated growth is driven by advancements in generative AI algorithms, the increasing adoption of precision medicine, the expansion of virtual clinical trials, a rising need for biologics optimization, and the integration of AI with cloud computing. Significant trends for the forecast period include AI-driven drug design optimization, predictive molecular modeling, virtual screening of compound libraries, the development of personalized medicine, and biopharmaceutical efficacy simulation.

Get Access To A Free Generative Artificial Intelligence (AI) In Pharmaceutical Market Report Sample:

https://thebusinessresearchcompany.com/sample_request?id=78894801&type=smp&name=Generative%20Artificial%20Intelligence%20%28AI%29%20In%20Pharmaceutical%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

The Key Driver Behind The Generative Artificial Intelligence (AI) In Pharmaceutical Market’s 30.9% CAGR

The growing emphasis on personalized medicine is anticipated to drive the expansion of generative artificial intelligence (AI) within the pharmaceutical market moving ahead. Personalized medicine tailors medical care to the individual characteristics, needs, and preferences of each patient, based on their genetic, environmental, and lifestyle factors. This heightened focus on personalized medicine is a result of advancements in genetic research and technology, enabling more precise and effective treatments customized for individual patients. Within pharmaceuticals, personalized medicine employs generative AI to develop tailored drug therapies, thereby enhancing treatment efficacy and improving patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, a significant increase from the six approvals in 2022. Therefore, the increasing focus on personalized medicine is propelling the growth of generative artificial intelligence (AI) in the pharmaceutical market.

Generative Artificial Intelligence (AI) In Pharmaceutical Market Classification: Main Segments And Detailed Subsegments

The generative artificial intelligence (AI) in pharmaceutical market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule

2) By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies

3) By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications

Subsegments:

1) By Small Molecule: Drug Discovery And Design, Lead Optimization For Small Molecule Compounds, Predictive Modeling For Pharmacokinetics And Toxicity, Virtual Screening Of Compound Libraries, Personalized Medicine Approaches For Small Molecule Therapies

2) By Large Molecule: Biologics Discovery And Development, Monoclonal Antibody Design, Protein Engineering And Optimization, Vaccine Development And Optimization, Predictive Models For Biopharmaceutical Efficacy And Safety.

Generative Artificial Intelligence (AI) In Pharmaceutical Market Strategic Shifts: What Leading Players Are Prioritizing

Leading companies in the generative artificial intelligence (AI) pharmaceutical market are creating new products, such as AI healthcare microservices, to improve drug discovery processes. These AI healthcare microservices are modular, cloud-based offerings that utilize artificial intelligence to enhance various healthcare functions, including drug discovery, medical imaging, and diagnostics. For example, in March 2024, Nvidia Corporation, a US-based technology firm, unveiled generative AI microservices. These services include optimized NIM AI models and workflows with APIs designed for constructing cloud-native applications. They provide advanced imaging, natural language, speech recognition, and digital biology features. Key tools such as Parabricks, MONAI, NeMo, Riva, and Metropolis are accessible as CUDA-X microservices, thereby streamlining workflows in drug discovery and genomics.

Generative Artificial Intelligence (AI) In Pharmaceutical Market Company Analysis: Major Industry Participants

Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited

Get Full Access To The Generative Artificial Intelligence (AI) In Pharmaceutical Market Report 2026:

https://thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-pharmaceutical-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Generative Artificial Intelligence (AI) In Pharmaceutical Market Global Regional Breakdown: Key Regions Analyzed

North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2025. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model